Skip to content
Alligator Bioscience

Alligator Bioscience

sv
  • About Alligator
    • Board of directors
    • Management
    • Collaborations and partnerships
    • Career
  • Research & development
    • Immunotherapy of cancer
    • Pipeline
      • ADC-1013 (mitazalimab)
      • ATOR-1015
      • ATOR-1017
      • ALG.APV-527
      • ATOR-1144
      • Research projects
    • Scientific publications
    • Technology platform
      • ALLIGATOR-GOLD®
      • FIND®
    • Scientific advisors and collaborators
  • Corporate governance
    • General meeting
    • Board of Directors and Management
    • Nomination committee
    • Audit Committee
    • Remuneration Committee
    • Remuneration
    • Auditors
    • Articles of association
    • Internal control
  • Investors
    • Share and shareholders
    • Analysts
    • IPO
    • Financial reports
      • Annual reports
      • Interim reports
    • Calendar
    • Presentations
    • Subscribe
  • News
    • Press releases
    • Frontier – A magazine about Alligator
    • Subscribe
  • Contact
  • SV

  • Alligator Bioscience - Innovating Tumor-Directed Immunotherapy

  • Cancer cure is our passion - research is our foundation

  • Tumor-directed immunotherapies for major unmet medical needs within cancer

  1. 1
  2. 2
  3. 3

Latest News

  • 13 Nov 2019 – Nomination Committee appointed in respect of AGM 2020 in Alligator Bioscience AB
  • 8 Nov 2019 – Aptevo Therapeutics and Alligator Bioscience present new preclinical data for ALG.APV-527 at the Society for Immunotherapy of Cancer 2019 Annual Meeting
  • 6 Nov 2019 – Alligator Bioscience: ATOR-1017 Induces Long-Lasting Immunity – New Preclinical Data to be presented at SITC 34th Annual Meeting
  • 24 Oct 2019 – Alligator Bioscience AB Interim report January-September 2019
More news

Calendar

  • 19 Nov 2019 ‐ Redeye Life Science Day, Stockholm
  • 20 Nov 2019 — 21 Nov 2019 ‐ 10th Annual Jefferies 2019 Healthcare Conference, London
  • 25 Nov 2019 ‐ Stora Aktiedagen, Stockholm
  • 25 Nov 2019 ‐ Nordea 2nd Annual Healthcare Seminar, Stockholm
  • 12 Dec 2019 ‐ DNB Nordic Healthcare Conference 2019, Oslo

The Alligator Movie

Watch the movie about Alligator Bioscience on youtube.

About

Alligator develops antibody-based pharmaceuticals for cancer treatment. The company specializes in the development of tumor-directed immunotherapies, in particular agonistic mono- and bispecific antibodies. The company is active in the early stages of drug development, from idea to clinical phase II studies.

Links

  • About Alligator
  • Research and development
  • Corporate governance
  • Investors
  • News
  • Contact

Contact

Alligator Bioscience AB
Medicon Village
Scheelevägen 2
SE-223 81 Lund
Sweden

Phone: + 46 (0)46 540 82 00

info@alligatorbioscience.com
ir@alligatorbioscience.com

Subscribe

Subscribe to get our pressreleases by email.

SUBSCRIBE

Alligator Bioscience

© Copyright 2018 - Alligator Bioscience AB

We use cookies for administering, monitoring and optimizing the website, and for analytical purposes, in accordance with what is stated in our cookie policy.I agreeI do not agree
Återkalla cookies